Fig. 7.
The scheme of autologous therapy with TUDCA-treated CKD-hMSCs: hMSC enhancement via increased concentration of PrPC. Reduction of mitochondrial functionality leads to decreased cellular proliferation and function, including decreased repair of damaged vascular tissue, ultimately unable to restore of kidney fibrosis. Increased in mitochondrial functionality leads to increased cellular proliferation, which enhances vascular repair of damaged cells. Healthier cellular state leads to increased autologous therapy of kidney fibrosis.